Gabriel Haas, MD, FACS

Medical Director Oncology
Astellas Pharmaceuticals Global Devleopment Inc
Northbrook, Illinois, United States

Disclosure information not submitted.

Presentation(s):

• eP812 - A Phase 3, Multicenter, Open-Label, Randomized, Placebo-Controlled Trial, for Ureteral Identification Using Pudexacianinium Chloride (ASP5354) in Patients Undergoing Abdominopelvic Surgery

  Monday, June 3, 2024
  10:36 AM – 10:41 AM ET, USA